Innovate UK

StimOxyGen is a biotechnology company focused on developing innovative, pH-responsive nanoparticles. These nanoparticles are designed to generate oxygen in hypoxic (low oxygen) tumors, enhancing the effectiveness of cancer treatments like radiotherapy and chemotherapy. The company's core technology involves a nanoparticle formulation that dissolves in the low pH environment of tumors, transiently producing oxygen and thereby maximizing the therapeutic effects of radiotherapy.

Constructive Bio is a biotechnology company that rewrites genomes to turn living cells into biofactories for sustainable materials and therapeutics. By controlling the genetic sequence, it enables the biosynthesis of enzymes, pharmaceuticals, and biomaterials while exploring chemical space beyond natural biology. The approach includes developing virus-resistant organisms and supporting next-generation bioprocesses and biopharmaceuticals.

Lant Medical is a health technology company specializing in the development of non-antibiotic treatments for Helicobacter pylori (H. pylori) infections. Their innovative therapy targets the root cause of the infection and its associated symptoms, providing an effective monotherapy or complement to existing treatments. This enables healthcare professionals to manage H. pylori infections more efficiently.

Lant Medical is a health technology company specializing in the development of non-antibiotic treatments for Helicobacter pylori (H. pylori) infections. Their innovative therapy targets the root cause of the infection and its associated symptoms, providing an effective monotherapy or complement to existing treatments. This enables healthcare professionals to manage H. pylori infections more efficiently.

Sequential Skin is a diagnostic platform focused on skin longevity and aging, leveraging expertise in genetics, epigenetics, and the skin microbiome. The company specializes in clinical microbiome testing for skin, scalp, and female health. Its primary offering is a skin health test that employs quantitative real-time PCR (qPCR) technology to analyze specific markers within the skin microbiome. This analysis provides individuals with a detailed understanding of their skin profile, helping them identify their unique skincare needs. By delivering personalized insights, Sequential Skin empowers individuals to make informed decisions about their skincare routines.

Circadacare specializes in improving the lives of residents and staff in care environments through innovative technology. Their solutions focus on enhancing wellness, promoting autonomy, reducing falls, and tracking behaviors using circadian lighting and advanced AI monitoring.

Axial3D specializes in 3D printing technology tailored for healthcare. It converts patient CT and MRI scan data into precise, personalized 3D models to enhance medical professionals' understanding of abnormalities, encourage innovative surgical techniques, and improve patient outcomes.

MediMusic is a health‑technology company that develops algorithmic music neuroscience solutions for medical and well‑being applications. Using artificial intelligence, it creates personalized playlists that lower heart rate and stimulate the vagus nerve, producing a positive physio‑endocrine response. The technology is designed to reduce stress and anxiety and to enhance the effectiveness of pain medication, and it is applied in contexts such as dementia care, anxiety treatment, and pain management.

Dia Beta Labs is a biotechnology company dedicated to improving the lives of individuals with metabolic diseases. It operates from Ulster, where it has access to advanced facilities and a network of experts. The company's focus is on developing therapeutic agents to address the decline of pancreatic health in patients, with the goal of achieving more sustainable and effective weight loss than current options. Its discovery platform uses industry-standard methodologies and models to identify and advance lead molecules for animal research.

Chromatwist develops innovative fluorescent dyes that become visible under UV light. Their patented technology platform enables the creation of fluorophores used in bio-sensing (like flow cytometry) and bio-imaging (such as multiphoton microscopy) within the healthcare sector.

Epitopea is a transatlantic biotechnology company focused on developing immunotherapies that target a novel class of tumor‑specific antigens. Using a proprietary pipeline that combines immunopetidomics, mass spectrometry, genomics and bioinformatics, the company identifies conserved, aberrantly expressed antigens hidden in cancer’s ‘junk’ DNA. These Cryptigen TSAs are shared across patients with the same cancer indication, allowing therapies to selectively eliminate malignant cells while sparing healthy tissue, with the goal of providing durable, low‑side‑effect treatments.

ScubaTx is a company focused on developing an advanced organ preservation system that utilizes the Persufflation method, a well-established technique aimed at enhancing organ transportation. By leveraging innovative software design, ScubaTx aims to provide significant cost savings for healthcare providers, thereby facilitating an expanded supply of viable organs for transplantation. The company’s technology is designed to protect and improve the condition of grafts during the preservation process, ultimately empowering clinicians worldwide to increase the availability of life-saving organs.

Lentitek is a cell and gene therapy company developing gene therapies and gene-modified cell therapies to broaden access to cures. It focuses on increasing the production yields of lentiviral vectors through its platform, using a novel promoter and proprietary production methods. The approach aims to deliver substantially higher yields, potentially reducing manufacturing costs and improving scalability for healthcare providers delivering gene therapies.

Theolytics Limited is a clinical-stage biotechnology company based in Oxford, United Kingdom, specializing in the development of oncolytic viral therapies to combat cancer. Founded in 2017, Theolytics utilizes a phenotypic screening platform that facilitates the discovery and development of effective, targeted therapeutic candidates designed for intravenous delivery. The company's innovative approach is aimed at creating category-changing cancer treatments that can address both solid and liquid tumors. In addition to advancing its internal pipeline of programs, Theolytics is also forming strategic partnerships to enhance and expedite the development of its therapeutic offerings, ultimately striving to provide innovative care options for patients.

Mestag Therapeutics is a biotechnology company focused on developing innovative therapies for cancer and inflammatory diseases through its unique fibroblast technology. The company leverages emerging insights into the role of activated fibroblast populations in disease progression to create therapeutics that disrupt fibroblast-mediated effects on immune cells. By targeting these mechanisms, Mestag aims to enhance treatment options and improve outcomes for patients suffering from rare and life-threatening conditions.

BoobyBiome operates a microbiome research platform and develops probiotic supplements for infants with compromised microbiomes, including premature babies, to promote gut health and immune development by closely mirroring the beneficial bacteria found in breast milk.

SynaptixBio is a biotechnology company focused on developing innovative therapies for severe leukodystrophies, particularly targeting TUBB4a Leukodystrophy. By addressing the root causes of these conditions, SynaptixBio aims to provide potential curative treatments that could significantly disrupt existing treatment practices. The company is dedicated to translating groundbreaking research into transformative therapeutic options, specifically by altering the expression of a mutated gene responsible for the disease. Through its efforts, SynaptixBio seeks to deliver lifesaving solutions to those affected by this acute subset of leukodystrophies.

Siloton is a medical device company specializing in ophthalmology. It designs and develops diagnostic imaging devices, notably a portable optical coherence tomography system, coupled with cloud-based digital health tools to enhance patient care and prevent avoidable blindness.

Awen Oncology is a pre-clinical stage pharmaceutical company focused on developing novel cancer therapies. It specializes in targeting 'developmentally-silent oncogenic drivers', which are genes that contribute to cancer growth but are not typically targeted by existing treatments. The company's approach combines expertise in cell and molecular biology with advanced structural biology and in-silico drug screening to rapidly and efficiently identify and develop effective cancer treatments.

Founded in 2009, MedAnnex is a UK-based biotechnology company dedicated to developing first-in-class antibody therapies for treating cancers and autoimmune diseases. Its lead product, annexuzlimab, targets annexin-A1 to inhibit cancer cell growth and autoimmune condition development.

Cumulus Neuroscience develops an AI-based digital biomarker platform to aid in the resolution of the most pressing healthcare challenges in neurodegeneration and psychiatry. Cumulus Neuroscience's platform is intended to provide the critical data and insight required for more rapid, robust, and cost-effective clinical trials that improve patient access to new therapies. The platform's novel insights change the future of clinical trials in brain disorders, allowing life-changing therapies to reach patients faster and more affordably.

ThirtyFiveBio is a biotechnology company developing novel genetically and pharmacologically validated protein modulators for treating severe gastrointestinal diseases.

Nuclera specializes in accelerating drug discovery by providing a protein prototyping system. Its eProtein Discovery™ platform enables scientists to rapidly produce and test proteins for research purposes.

BiVictriX Therapeutics Ltd. is a drug discovery and development company based in Alderley Edge, United Kingdom, focused on creating bispecific antibody drug conjugates to address unmet medical needs in blood cancer. Established in 2016, the company leverages its proprietary Bi-Cygni technology to develop innovative therapies for various types of cancers, including Acute Myeloid Leukaemia. BiVictriX specializes in oncology and haematological malignancies, offering a range of services that encompass biotherapeutics, immunotherapy, antibody research, and drug development. The company aims to advance its pharmaceutical products through rigorous development processes to improve treatment outcomes for patients with serious medical conditions.

Fuse Diagnostics develops innovative diagnostic products designed to deliver lab-quality information quickly and at a lower cost. Their solutions cater to food and water testing, bioprocessing industries, and cell biology research.

Founded in London in 2016, LIfT BioSciences develops a proprietary platform for allogeneic innate immuno-cell therapy. Its Neutrophil Only Leukocyte Infusion Therapy (N-LIfT®) enables scalable production of Immunomodulatory Alpha Neutrophils (IMAN®s) from induced pluripotent stem cells (iPSCs), offering potential mono or combo therapies.

The University of Bristol is a red brick research university that offers a range of educational courses and services. The university is organized into six academic facilities: Faculty of Arts, Faculty of Engineering, Faculty of Medical and Veterinary Sciences, Faculty of Science, Faculty of Medicine and Dentistry, and Faculty of Social Sciences and Law. These faculties together award a range of academic degrees spanning bachelor's and master's degrees as well as junior doctorates and higher doctorates. University of Bristol was established in 1876 and is based in Bristol, United Kingdom.

Monument Therapeutics is a biotechnology company focused on developing drugs for treating serious diseases of the central nervous system. Its innovative approach employs proprietary digital biomarkers to reduce patient heterogeneity, enabling more targeted neuroscience drug development in areas with unmet medical needs.

Cumulus Neuroscience develops an AI-based digital biomarker platform to aid in the resolution of the most pressing healthcare challenges in neurodegeneration and psychiatry. Cumulus Neuroscience's platform is intended to provide the critical data and insight required for more rapid, robust, and cost-effective clinical trials that improve patient access to new therapies. The platform's novel insights change the future of clinical trials in brain disorders, allowing life-changing therapies to reach patients faster and more affordably.

Presymptom Health is a medical technology company dedicated to advancing healthcare through the development of pre-symptomatic diagnostic tests and clinical decision support algorithms. The company focuses on creating innovative blood tests designed to detect illnesses at an early stage, particularly aiming to predict the onset of sepsis up to three days before symptoms manifest. By enabling earlier intervention, Presymptom Health seeks to improve critical care outcomes and enhance patient management, ultimately contributing to better survival rates and healthcare efficiency.

IXICO plc, established in 1995 and headquartered in London, specializes in providing data analytics services to the global biopharmaceutical industry. The company focuses on the collection, analysis, management, and reporting of data generated during clinical studies, with a particular emphasis on neurological diseases. IXICO's key technologies include Assessa, a digital platform for clinical decision support, and TrialTracker, a comprehensive imaging service workflow management system. The company's end-to-end imaging services are primarily applied in the fields of Alzheimer's, Parkinson's, Huntington's, multiple sclerosis, cerebrovascular, and progressive supranuclear palsy diseases. IXICO's services are utilized to select patients for clinical trials, assess drug safety and efficacy, and for post-marketing surveillance. The company works with pharmaceutical companies, biotech firms, academia, and medical charities worldwide.

Founded in 2017, SolasCure is a biotechnology company based in Wales, UK. It specializes in developing innovative hydrogel treatments for patients with chronic wounds. Its flagship product, Aurase, facilitates wound debridement, removing dead or infected tissue to enhance healing.

Cortirio is a developer of portable brain imaging technology aimed at improving the diagnosis and treatment of traumatic brain injuries, which are a leading cause of death and disability among individuals under 40. The company designs portable scanners that utilize near-infrared imaging to deliver high-resolution, point-of-care medical imaging. These wearable devices provide critical information throughout the clinical pathway, facilitating automatic analysis and efficient data transfer. By equipping clinicians with rapid and accurate diagnostic tools, Cortirio enhances decision-making processes and improves care for patients suffering from brain injuries and strokes, ultimately aiming to reduce treatment times and prevent long-term disability or death.

Neobe Therapeutics provides immunotherapies, clinical trials, research, and tumor-colonizing bacteria engineering services.

Aelius Biotech specializes in developing models of the mucosal surfaces within the human body. Currently, they focus on simulating the gastrointestinal tract and airways, with ongoing efforts to model the eye and cervico-vaginal tract.

AMPLY Discovery uses machine learning and synthetic biology to mine large biological datasets and identify novel drug and nutraceutical candidates. The company combines an in silico and in vitro platform to discover first-in-class molecules and to tackle cancer, metabolic diseases, and multidrug-resistant infections. It develops a drug discovery studio that leverages artificial intelligence to digitize life’s natural diversity and to identify putative drug candidates based on function, enabling researchers to pursue new therapeutic molecules for hard-to-treat diseases.

Lucida Medical develops artificial intelligence–based healthcare technology to aid clinicians in the detection and diagnosis of cancer. Its platform analyzes imaging data from MRI and integrates imaging and multi-omics biomarkers and reporting tools to support cancer screening and diagnosis, with the aim of making detection more accurate, accessible, and faster while reducing costs. The company’s first product, Pi, is designed to assist in diagnosing prostate cancer using multiparametric or diffusion MRI and is a CE marked medical device.

Mesenbio is a preclinical biopharmaceutical company based at the University of York, specializing in cell-derived therapies. It has developed a unique technique known as Cell Line Extracellular Vesicle Release (CLEVR), which aims to enhance the treatment pipeline by addressing significant challenges in extracellular vesicle therapy. The company focuses on creating innovative treatments, including a novel therapy for arthritis derived from engineered human stem cells. By unlocking the potential of extracellular vesicles, Mesenbio seeks to transform medical approaches to musculoskeletal diseases, thereby providing more effective therapeutic options.

The University of Edinburgh, established in 1583, is a prestigious institution located in Edinburgh, United Kingdom. It is renowned globally for its academic excellence, offering a wide range of disciplines, including its renowned Medical School and Law School. As one of Scotland's ancient universities, it is committed to delivering high-quality education, conducting cutting-edge research, and fostering innovation to address global challenges.

Cyted specializes in digital diagnostic infrastructure, utilizing AI and innovative biomarkers for early disease detection. Its mission is to transform diagnostic methods, aiming for a world where diseases are prevented rather than treated.

CellRev is a biotechnology company specializing in process intensification for cell manufacturing. Its proprietary technology enables the transition from batch to continuous processing of adherent cells, increasing yields while reducing operating costs and capital expenditure.

The Sixth Sense in medical Diagnostics. At AINOSTICS we are working to identify the earliest biological signs of some of our society’s most devastating neurodegenerative conditions such as Alzheimer’s disease, Huntington's and MS, providing the best chance of success in the development of potential preventions and therapeutics by Pharma, and precise treatment planning by clinicians. We combine the most exciting medical imaging innovations with the best of artificial intelligence solutions to unlock the future of personalised diagnosis, prognosis, and therapy monitoring and planning.

SynaptixBio is a biotechnology company focused on developing innovative therapies for severe leukodystrophies, particularly targeting TUBB4a Leukodystrophy. By addressing the root causes of these conditions, SynaptixBio aims to provide potential curative treatments that could significantly disrupt existing treatment practices. The company is dedicated to translating groundbreaking research into transformative therapeutic options, specifically by altering the expression of a mutated gene responsible for the disease. Through its efforts, SynaptixBio seeks to deliver lifesaving solutions to those affected by this acute subset of leukodystrophies.

Spirecut is a MedTech company specializing in patented surgical instruments for treating carpal tunnel syndrome and trigger finger via ultrasound-guided surgery. Its technique avoids skin incisions and post-operative wounds, enabling patients to resume daily activities immediately.

Physiomics Plc is a consulting firm based in Oxford, United Kingdom, specializing in services for pharmaceutical companies in the realms of quantitative pharmacology and computational biology. Established in 2001, the company utilizes its proprietary Virtual Tumour predictive software to offer modeling, simulation, and data analysis services, primarily focused on oncology research and development. By combining systems biology with advanced mathematical techniques, Physiomics aims to optimize dosing and scheduling of oncology drugs during pre-clinical and clinical trials, enhancing the efficacy of drug combinations and streamlining the overall drug development process. The company's operations extend across the United Kingdom, the European Union, Switzerland, and the United States, with a commitment to advancing personalized medicine through innovative technology.

Laverock Therapeutics develops a gene silencing platform for creating programmable, allogeneic cell therapies.

Brainomix develops AI-powered imaging biomarkers for neurological and cerebrovascular disorders. Its software suite, including e-ASPECTS, e-CTA, and e-Mismatch, automates brain scan analysis to assist physicians in making timely treatment decisions for stroke patients.

ThirtyFiveBio is a biotechnology company developing novel genetically and pharmacologically validated protein modulators for treating severe gastrointestinal diseases.

Founded in 2012, Stablepharma specializes in developing processes for vaccine stabilization. Its flagship product, Stablevax, enables precise dosage pre-loading into syringes at manufacture, eliminating wastage. The company's technology platform converts existing vaccines and diagnostics into thermostable products, addressing global cold chain challenges.

Jude is a healthcare company focused on addressing bladder-related issues and raising awareness about incontinence. It provides a range of bladder care solutions, including access to medical specialists who offer advice through social media platforms, virtual workshops, and private chat sessions. In addition to educational resources, Jude supplies health products designed to help individuals understand their conditions and manage them effectively. By promoting open discussions and providing expert guidance, Jude aims to empower individuals to lead leak-free lives and break the stigma surrounding bladder health.

AstronauTx focuses on restoring healthy function of astrocytes, a type of brain cell crucial for neuronal health and blood-brain barrier integrity. Its primary goal is to develop treatments targeting astrocyte dysfunction in dementias like Alzheimer's disease.

Plasticell is a biotechnology company focused on developing innovative therapeutic solutions through advanced cell culture and drug discovery platforms. By investigating the biochemical mechanisms that govern stem cell behavior, Plasticell aims to create regenerative small molecule drugs that support tissue development and repair. The company offers comprehensive support for researchers in cell biology by enabling the testing of numerous cell culture variables, thereby optimizing laboratory protocols for various outcomes. This approach facilitates the differentiation of cells and enhances processes such as gene transduction and protein production, ultimately contributing to the advancement of novel therapies in regenerative medicine.

NK:IO is a biotechnology company focused on developing natural killer cell-mediated immunotherapies for cancer. The company develops both cell therapies and small molecule therapeutics designed to target cancer and enhance the tumor-killing activity of natural killer cells.

Ramanomics extracts microorganisms and their antimicrobial profiles from clinical specimens.

Corryn is a biotechnology company specializing in the development of advanced wound care solutions. Its flagship product, Heals device, employs contactless technology to revolutionize the treatment of chronic and complex wounds.

SMi Systems is a biomedical research company that develops single-molecule discovery and diagnostic tools. Its automated, high-throughput platform uses super-resolution microscopy coupled with deep learning for multi-omic detection, enabling drug developers to observe molecular interactions across various diseases.

SMi Systems is a biomedical research company that develops single-molecule discovery and diagnostic tools. Its automated, high-throughput platform uses super-resolution microscopy coupled with deep learning for multi-omic detection, enabling drug developers to observe molecular interactions across various diseases.

Autolomous develops pragmatic software solutions for cell and gene therapy manufacturers. Its platform, autoloMATE®, offers end-to-end solutions including resource scheduling, electronic batch records management, insights reporting, review, and release activities. The platform aligns with US FDA, EU EMA & UK MHRA guidance and is certified ISO 27001:2013 (information security), ISO 9001:2015 (quality management), and ISO 14001:2015 (environmental management).

The Cell and Gene Therapy Catapult is a UK-based centre of excellence dedicated to advancing the cell and gene therapy sector globally. Supported by Innovate UK, it aims to facilitate the translation of early-stage research into commercially viable therapies. With over 120 experts and state-of-the-art laboratories at Guy's Hospital in London, CGT Catapult is building a £55m large-scale manufacturing centre to accelerate market access for these therapies.

GG Care helps care residents stay independent and help carers monitor their well-being, comfort, and mood. They serve people with dementia maintain daily routines and stay socially connections shown to reduce cognitive decline and increase happiness and creates an environment to help reduce agitation - significantly reducing the cost of care.

The Sixth Sense in medical Diagnostics. At AINOSTICS we are working to identify the earliest biological signs of some of our society’s most devastating neurodegenerative conditions such as Alzheimer’s disease, Huntington's and MS, providing the best chance of success in the development of potential preventions and therapeutics by Pharma, and precise treatment planning by clinicians. We combine the most exciting medical imaging innovations with the best of artificial intelligence solutions to unlock the future of personalised diagnosis, prognosis, and therapy monitoring and planning.

SyncVR Medical is an extended reality platform that uses virtual and augmented reality technologies to enhance healthcare. It provides a broad range of XR applications and access to third-party healthcare apps, enabling hospitals, patients, and medical professionals to improve treatment experiences and expand access to innovative digital care. The platform serves European and UK healthcare institutions, supporting numerous facilities and a growing network of developers that supply XR medical apps through its ecosystem.

ScubaTx is a company focused on developing an advanced organ preservation system that utilizes the Persufflation method, a well-established technique aimed at enhancing organ transportation. By leveraging innovative software design, ScubaTx aims to provide significant cost savings for healthcare providers, thereby facilitating an expanded supply of viable organs for transplantation. The company’s technology is designed to protect and improve the condition of grafts during the preservation process, ultimately empowering clinicians worldwide to increase the availability of life-saving organs.

Lindus Health is a clinical research organization that specializes in managing end-to-end clinical trials for healthcare and biotechnology companies. The company offers services such as ethics and IRB submissions, trial monitoring, data management, biostatistics, regulatory affairs, and payor relations. Lindus Health employs an in-house team of clinicians and researchers to accelerate the clinical trial process using its proprietary software platform, Curebase OS, which automates workflows and reduces manual inefficiencies. The company also leverages real-world patient data for precise participant recruitment and smarter trial design, aiming to make clinical trials faster and more cost-effective while improving patient treatment outcomes.

Maxion Therapeutics develops a novel platform to generate antibody-like therapeutics targeting ion channels and GPCR-driven diseases. The platform incorporates venom-derived knottins into antibody surfaces to create mixtures with optimized drug-like properties, enabling treatments for conditions such as chronic pain, autoimmune disorders, and heart disease. The company aims to deliver long-acting, safe, and effective medications against previously inaccessible targets.

Founded by specialists in nanotechnology, medicinal chemistry, and artificial intelligence, Nanovery aims to enable early detection of cancer through a rapid and affordable blood test. Its core technology involves AI-powered nanorobots that capture circulating tumor DNA and emit a fluorescent signal for point-of-care detection.

QV Bioelectronics develops an innovative electric field therapy implant, GRACE, designed to extend the lives of brain tumor patients while maintaining their quality of life. This first-of-its-kind device targets glioblastoma, a cancer with poor outcomes, by slowing tumor growth and sparing healthy tissue.

GenoMe Diagnostics is a biotechnology company focused on developing innovative blood tests for early cancer detection. Its flagship product, OvaME, aims to improve the current standard of CA125 blood tests.

Doctoria by Ozana is an AI-powered platform transforming communication in healthcare and law enforcement by breaking language barriers and streamlining documentation. Our solutions offer real-time medical interpretation, automated clinical note generation, and secure multilingual tools that enhance efficiency, compliance, and safety. Designed for scalability, Doctoria addresses critical gaps in high-pressure environments, thereby reducing costs and improving outcomes for hospitals, emergency responders, and public institutions.

LightOx is a biotechnology company focused on developing innovative molecular tools and light-activated therapeutics for cancer treatment. The company offers a unique range of fluorescent probes that are smaller than existing commercial options, allowing for versatile use in imaging, therapeutics, and assay development. These probes can function as freely-moving agents within cells or be coupled with flexible linkers to provide specificity for various research applications. LightOx is dedicated to improving patient outcomes by creating targeted drug compounds that selectively eliminate tumor cells while minimizing damage to surrounding healthy tissues. This approach aims to enhance the efficiency of cancer treatment and contribute to better long-term health for patients.

Myma Medical is a bright, cutting-edge start-up with a model to greatly improve the experiences of people who are having fertility issues.

EnsiliTech is a biopharmaceuticals company focused on preserving the integrity of vaccines and other biological materials. The company has developed a novel ensilication technology that utilizes protective silica nanoshells to shield vaccine components from environmental degradation. This innovative approach aims to prevent vaccine spoilage, thereby enhancing the shelf-life of these critical biological products. By improving the stability and accessibility of vaccines, EnsiliTech seeks to reduce waste and contribute to global vaccination efforts, ensuring that more people can benefit from life-saving immunizations.

EnsiliTech is a biopharmaceuticals company focused on preserving the integrity of vaccines and other biological materials. The company has developed a novel ensilication technology that utilizes protective silica nanoshells to shield vaccine components from environmental degradation. This innovative approach aims to prevent vaccine spoilage, thereby enhancing the shelf-life of these critical biological products. By improving the stability and accessibility of vaccines, EnsiliTech seeks to reduce waste and contribute to global vaccination efforts, ensuring that more people can benefit from life-saving immunizations.

Healthera Ltd., established in 2015 and headquartered in Cambridge, UK, specializes in developing digital health solutions. Its flagship product, Healthera, is a pharmacy-integrated medication management app that offers automatic prescription reminders, smart labelling, scheduling, health condition tracking, and professional advice from pharmacists. Additionally, Healthera operates a healthcare marketplace that connects patients with local pharmacies and GPs, enabling faster medicine delivery and personalized care. The company partners with over 1000 pharmacies and Clinical Commissioning Groups (CCGs) across the UK, reaching over 20 million people. Healthera's technology is accredited by NHS Digital and aims to improve prescribing efficiency, patient experience, and reduce wastage within the NHS.

Amber Therapeutics specializes in developing advanced bioelectronic therapies that can sense and adapt, aiming to enhance clinical outcomes for patients with functional disorders of the peripheral nervous system.

The Medicines Discovery Catapult is the centre of national expertise for the discovery of medicines.

LabGenius Ltd is a biopharmaceutical company based in London, United Kingdom, focused on discovering and developing new protein therapeutics to address unmet medical needs, including conditions like Inflammatory Bowel Disease. Founded in 2012, the company utilizes a machine learning-driven evolution engine and a robotic platform known as EVA, which is capable of designing, conducting, and learning from its own experiments. This innovative approach integrates advanced technologies from synthetic biology, robotics, and machine learning, enabling the engineering of protein drugs with enhanced properties such as protease stability and tissue penetration. By leveraging these cutting-edge methodologies, LabGenius aims to provide physicians with access to novel protein therapeutics that are developed through automation and intelligent design.

Drill Surgeries is a company dedicated to enhancing the outcomes of trauma and orthopedic surgeries through its innovative AI-powered navigation system. This technology aims to significantly reduce the failure rate of surgeries from 36% to less than 4% by providing real-time guidance during osteosynthesis procedures. By employing proprietary AI algorithms and mixed reality technologies, Drill Surgeries facilitates a remarkable 83% reduction in operating room time. Additionally, the company’s solutions eliminate the need for unnecessary X-rays, leading to substantial cost savings of approximately $2,000 per operation for hospitals. Through these advancements, Drill Surgeries empowers doctors to perform complex procedures more efficiently and effectively, ultimately improving patient care and operational efficiency in healthcare settings.

Metallo Bio's focus is on the development of two lead chemicals that represent a pioneering new class of antibiotics, with the goal of addressing the rising issue of antimicrobial resistance.

Aten Therapeutics specializes in developing novel therapeutic antibodies targeting fundamental control pathways associated with major diseases. Their experienced management team aims to extend and improve patients' lives by creating powerful new treatments.

AMPLY Discovery uses machine learning and synthetic biology to mine large biological datasets and identify novel drug and nutraceutical candidates. The company combines an in silico and in vitro platform to discover first-in-class molecules and to tackle cancer, metabolic diseases, and multidrug-resistant infections. It develops a drug discovery studio that leverages artificial intelligence to digitize life’s natural diversity and to identify putative drug candidates based on function, enabling researchers to pursue new therapeutic molecules for hard-to-treat diseases.

Nolea Health is a healthcare recruitment platform focused on mental health talent. Its AI-powered platform accelerates sourcing, evaluation, and engagement of clinical professionals for healthcare organizations. It connects verified mental health clinicians with open roles, helping address clinician shortages, streamline hiring, and improve flexibility and job satisfaction for clinical staff. The platform draws on data from more than two hundred healthcare sources, provides AI-driven candidate insights and personalized outreach, and integrates with applicant tracking systems, enabling recruitment agencies to fill hard-to-reach clinical roles faster and with greater accuracy.

BoobyBiome operates a microbiome research platform and develops probiotic supplements for infants with compromised microbiomes, including premature babies, to promote gut health and immune development by closely mirroring the beneficial bacteria found in breast milk.

BoobyBiome operates a microbiome research platform and develops probiotic supplements for infants with compromised microbiomes, including premature babies, to promote gut health and immune development by closely mirroring the beneficial bacteria found in breast milk.

Stemnovate Limited is a biotechnology company based in Cambridge, United Kingdom, that specializes in developing innovative tools and technologies for drug screening and safety testing. Established in 2016, the company offers a range of products including induced pluripotent stem cells, primary human and multispecies cells, and a comprehensive cell culture and analysis package. Stemnovate employs advanced devices such as micro physiological systems and microfluidic technologies to facilitate research and development. One of its notable projects, the "Liver on chip," focuses on liver toxicity testing and integrates cellular reprogramming, stem cell research, and organ-on-chip technology. The company also provides services in cell reprogramming, differentiation, and application development, catering to a diverse clientele that includes pharmacists, contract research organizations, small to medium enterprises, and academic institutions.

Eleven Therapeutics is a biotechnology company pioneering AI-driven medicinal nucleic acids. It specializes in developing extended durability mRNA therapeutics, targeting unmet medical needs in metabolic, endocrinologic, and infectious diseases.

Sequential Skin is a diagnostic platform focused on skin longevity and aging, leveraging expertise in genetics, epigenetics, and the skin microbiome. The company specializes in clinical microbiome testing for skin, scalp, and female health. Its primary offering is a skin health test that employs quantitative real-time PCR (qPCR) technology to analyze specific markers within the skin microbiome. This analysis provides individuals with a detailed understanding of their skin profile, helping them identify their unique skincare needs. By delivering personalized insights, Sequential Skin empowers individuals to make informed decisions about their skincare routines.

Metallo Bio's focus is on the development of two lead chemicals that represent a pioneering new class of antibiotics, with the goal of addressing the rising issue of antimicrobial resistance.

Neumind develops mobile solutions for people with neurological conditions and injuries. Its app Alfred provides practical and therapeutic support for patients and their caregivers, helping individuals live more independently and maintain function. The platform uses smartphone technology to support key cognitive functions, stimulate neural pathways, and establish behaviours and strategies grounded in neurorehabilitation and cognitive-behavioral science. Founded in 2019 and based in Great Shelford, Cambridge, Neumind aims to enable people affected by brain injuries, dementia, and related conditions to lead more independent, functional lives.

Founded in 2018 by industry veterans in neuroscience drug discovery, NRG Therapeutics is a biotechnology company dedicated to developing therapeutic approaches that restore mitochondrial function. Their primary focus is slowing or halting the progression of neurodegenerative diseases like Parkinson's and Alzheimer's through innovative drug discovery.

BoobyBiome operates a microbiome research platform and develops probiotic supplements for infants with compromised microbiomes, including premature babies, to promote gut health and immune development by closely mirroring the beneficial bacteria found in breast milk.

We already know that upto 50% of patients struggle to take their medicines – patients are not well-supported and too often it remains a hidden problem until it's too late. CONNECT Care want to change that: empowering patients and, at the same time, using data-driven insights to enable clinicians and carers to provide better support in real-time.

Kynos Therapeutics develops novel therapies targeting Kaiser-Meyer-Olkin (KMO), a key enzyme involved in inflammation, immunity, and metabolism. Its focus is on indications with unmet medical needs.

Medwise.ai operates a customizable search platform that uses natural language processing and artificial intelligence technologies to provide clinical decision support for doctors. Its real-world data offers insights to various healthcare stakeholders, enabling doctors to organize medical knowledge and enhance patient care outcomes.

GenoMe Diagnostics is a biotechnology company focused on developing innovative blood tests for early cancer detection. Its flagship product, OvaME, aims to improve the current standard of CA125 blood tests.

Founded in 2016, Five Alarm Bio is a biotechnology company based in Cambridge, UK. It focuses on drug discovery to develop anti-aging therapies using a small molecule approach, aiming to enhance the body's defenses against aging-related damage and diseases.

Eleven Therapeutics is a biotechnology company pioneering AI-driven medicinal nucleic acids. It specializes in developing extended durability mRNA therapeutics, targeting unmet medical needs in metabolic, endocrinologic, and infectious diseases.

Sixfold Bioscience Inc. is a London-based company founded in 2018 that specializes in the development of innovative drug delivery techniques aimed at treating cancer patients. The company focuses on engineering programmable oligonucleotide delivery systems that are designed to deliver RNA specifically to diseased cells. This targeted approach enhances the efficacy of treatments while minimizing side effects, positioning Sixfold Bioscience at the forefront of advancements in cancer therapy.

We already know that upto 50% of patients struggle to take their medicines – patients are not well-supported and too often it remains a hidden problem until it's too late. CONNECT Care want to change that: empowering patients and, at the same time, using data-driven insights to enable clinicians and carers to provide better support in real-time.

Abtrace offers AI-driven solutions that enhance medical expertise, reducing duplication and improving patient safety. Its machine learning algorithms assist healthcare professionals in managing current diseases, detecting new conditions early, and making informed decisions.